Development News Edition
Give Feedback

CSIR develops new Clot buster, PEGylated Streptokinase for people suffering from ischemic stroke

Epygen is the first company in India with an exclusive license of this Novel Biological Entity (NBE) thrombolytic protein for ischemic stroke. 


Government Press Release Last Updated at 12 Aug 2018, 13:08 IST India
CSIR develops new Clot buster, PEGylated Streptokinase for people suffering from ischemic stroke
  • Epygen is the first company in India with an exclusive license of this Novel Biological Entity (NBE) thrombolytic protein for ischemic stroke. (Image Credit: Twitter)

A new Clot buster, PEGylated Streptokinase - a Novel Biological Entity developed by Dr. Girish Sahni, DG, CSIR and Secretary, DSIR and his team of inventors at CSIR-Institute of Microbial Technology (CSIR-IMTECH), Chandigarh is all set to revolutionize the treatment of ischemic strokes.

Ischemic stroke is a condition caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries.

According to the American Stroke Association (ASA), brain strokes are the second leading cause of death in the world with a staggering 15 million people affected causing 11 million people either die or become permanently disabled.

Surprisingly, the prevalence of stroke is much higher in India than the West and about 87% of all strokes are ischemic strokes.

CSIR-IMTECH and Epygen Biotech Pvt. Ltd., Mumbai, have entered into an agreement for the latter to develop PEGylated Streptokinase for treatment of Ischemic Stroke.

Epygen is the first company in India with an exclusive license of this Novel Biological Entity (NBE) thrombolytic protein for ischemic stroke.

Epygen Biotech Pvt Ltd is a biopharmaceutical company, engaged in research and manufacturing of Therapeutic Proteins for Oncology, Cardiovascular and Immune disorders.

PEGylated Streptokinase, the novel recombinant protein Thrombolytic molecule has been precisely engineered through decades of research for enhanced proteolytic stability and extended plasma half-life, fibrin-specificity and associated clot specificity, with reduced immuno-reactivity which would be significant attributes with unmistakable clinical advantages such as reduced probability of hemorrhage over current treatment regimens of thrombolytic drugs for acute stroke.

These are huge advantages with a potential to transform the way ischemic stroke, deep-vein thrombosis, pulmonary embolism and acute myocardial infarction are treated around the globe, especially in the developing world.


add banner

LEAVE COMMENT

Download our Android App on Google Play